BioCentury
ARTICLE | Clinical News

Endocyte stops enrollment in Phase Ia/Ib solid tumor trial of EC1456

June 9, 2017 7:53 PM UTC

Endocyte Inc. (NASDAQ:ECYT) will stop enrollment in the Phase Ib portion of an open-label, U.S. Phase Ia/Ib trial of twice-weekly 6 mg/m2 EC1456 in up to 40 folate receptor-positive non-small cell lung cancer (NSCLC) patients. The company said “multiple dosing schedules did not yield the level of clinical activity necessary to support continued advancement.” The trial’s dose-escalation Phase Ia portion evaluated EC1456 in patients with advanced solid tumors irrespective of folate receptor expression.

EC1456 is a small molecule drug conjugate consisting of folate (vitamin B9) linked to tubulysin B hydrazide (TubBH). The trial's primary endpoints included maximum tolerated dose (MTD), recommended Phase II dose and safety for the Phase Ia portion and response for the Phase Ib portion...